XNW-1011 is under clinical development by Evopoint Bioscience and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XNW-1011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XNW-1011 is under development for the treatment of B-cell malignancies including relapsed and refractory chronic lymphocytic leukemia / small cell lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia, diffuse large B-cell lymphoma, rheumatoid arthritis, pemphigus, neuromyelitis optica spectrum disorder, SLE and Chronic kidney disease (renal diseases). It is administered through oral route and formulated in the form of capsule. The drug candidate acts by targeting Bruton’s tyrosine kinase (BTK) and a new chemical entity (NCE).
Evopoint Bioscience overview
Evopoint Bioscience, formerly Suzhou Sinovent Pharmaceuticals, is a biopharmaceutical company that involved in development of therapeutics for oncology, autoimmunity, and infectious diseases. The company is headquartered in Suzhou, Jiangsu, China.
For a complete picture of XNW-1011’s drug-specific PTSR and LoA scores, buy the report here.